The genetic toxicity of methylphenidate: a review of the current literature (pages 756–764)
Suzanne M. Morris, Dayton M. Petibone, Wei-Jiun Lin, James J. Chen, Benedetto Vitiello, Kristine L. Witt and Donald R. Mattison
Version of Record online: 15 FEB 2012 | DOI: 10.1002/jat.2721
The symptoms of Attention Deficit/Hyperactivity Disorder (ADHD) are effectively treated with methylphenidate (MPH). In 2005, reported increases in cytogenetic damage in the lymphocytes of MPH-treated pediatric patients caused world-wide concern. Numerous studies were initiated to verify or refute the findings. As reviewed in this communication, neither the laboratory animal nor human subject studies found an increase in MPH-induced genetic damage. The subsequent studies do not support the initial hypothesis that MPH treatment increases the risk of genetic damage in ADHD patients.